Aristolochic acid (AA) nephropathy is complicated with early onset and severe anemia. The molecular pathological mechanism of AA-induced anemia remains unclear. The aim of this study was to evaluate the putative pathological roles of the erythropoietin receptor (EPOR) in AA-induced anemia in both AA nephropathy zebrafish and cultured human renal tubular cells (HK2). Immunofluorescence staining experiments revealed that AA colocalizes with the EPOR in zebrafish embryos as well as in the cytoplasm of HK2 cells. After exogenous EPO stimulation, the EPOR was detected in the plasma membrane of HK cells. However, cotreatment with AA and EPO inhibited EPOR signaling and its membrane localization upon EPO stimulation. The results of studies with a protein synthesis inhibitor and a lysosome inhibitor revealed that AA accelerates the lysosomal degradation of EPOR. The molecular docking results suggest that AA may interact with the N-terminus of EPOR. Together with the results of light absorption and in vitro competition assays, we concluded that AA treatment impairs EPOR membrane localization, accelerates its lysosomal degradation, and consequently downregulates EPOR signaling by direct targeting. The results of this study may further detail the pathological mechanism of severe anemia complicated with AA nephropathy.
Aristolochic acids (AAs) are a family of compounds commonly found in Chinese herbal medicine containing Aristolochia spp. AA-I is the most abundant AA (Heinrich et al., 2009; Schmeiser et al., 2009) . AAs are known to be strong carcinogens and are significantly associated with the development of urothelial cancer in humans (Hoang et al., 2013; Lai et al., 2010) . AAs are also cytotoxic nephrotoxins and are considered causative agents in Balkan endemic nephropathy and Chinese herb nephropathy (De Broe, 2012; Gluhovschi et al., 2011) .
The potential worldwide population exposure of AA is enormous. AA nephropathy is significantly associated with the development of chronic kidney disease and acute kidney injury and with a high long-term risk for renal failure (Hutton et al., 2012; Yang et al., 2012; Zhang et al., 2013) . Patients with AA nephropathy exhibit an unusually rapid progression toward end-stage renal disease. Previous studies have shown that the 2-year actuarial renal survival rate of patients with AA nephropathy is 17% compared with 74% in a control group with other tubulointerstitial nephropathies (Reginster et al., 1997) .
In addition, AA nephropathy is complicated with early onset and severe anemia, and this anemia is more severe than expected based on the degree of renal failure Reginster et al., 1997 ). An early destruction of cortical peritubular cells producing erythropoietin (EPO), hemolysis, and iron deficiency has been proposed as possible mechanisms for the anemia associated with AA (Reginster et al., 1997) . Our previous studies on the nephrotoxicity of AA using a zebrafish model revealed that AA causes significant kidney and heart malformations, anemia, impaired blood circulation, and the accumulation of red blood cells (Ding and Chen, 2012) . However, the detailed molecular pathological mechanisms responsible for AA-related anemia remain unclear.
This study aimed to elucidate the pathological mechanisms of AA-related anemia. Impaired EPO production is the main cause of anemia in patients with chronic kidney disease (Sato and Yanagita, 2013) . It has been hypothesized that AA may impair EPO/erythropoietin receptor (EPOR) signaling. A series of dose-dependent AA exposure experiments both in vivo and in vitro were performed to test this hypothesis.
MATERIALS AND METHODS
Fish care and AA treatment. Mature zebrafish (AB strain) were maintained and their embryos were produced and staged using standard procedures (Westerfield, 2000) . For AA treatment, zebrafish embryos developed at 72 hpf were collected and exposed to 5 ppm AA for 7 h. At 79 hpf, the embryos were collected, fixed, and subjected to immunofluorescence labeling and confocal microscope analysis.
Cell culture and treatment. Human renal tubular HK2 cells were cultured as reported previously (Nightingale et al., 2004) . HK2 cell cultures at $70% confluence were synchronized under serum-free conditions for 48 h. The starved HK2 cells were cultured under serum-free conditions for 16 h. The treatment conditions and concentrations of experimental agents, including AA (CH 3 CONHC 6 H 4 OH; Sigma, St Louis, Missouri), recombinant EPO (Roche, Basel, Switzerland), cycloheximide (Sigma), and bafilomycin A1 (Sigma), are illustrated in the figure legends.
Western blotting analysis. The total protein was extracted using a commercial kit according to the manufacturer's instructions (Protein Extraction Kit, Millipore, Billerica, Massachusetts). Then, 30 lg of protein from each sample was mixed with sample-loading buffer and loaded onto separate lanes on a 12% sodium dodecyl sulfate-polyacrylamide gel. The proteins were electrotransferred onto polyvinylidene fluoride membranes (0.2 lm: Immun-Blot, Bio-Rad) and then immunoblotted with antibodies against EPOR (Abcam, Cambridge, Massachusetts), phosphorylated EPOR (Abcam), Erk1/2-p (Thr202/Tyr204) (Cell Signaling, Denver, Massachusetts), Akt-p (Ser473) (Cell Signaling), phospho-Jak (Abcam), and b-actin (Abcam). The intensity of each band was quantified using the NIH Image software (Bethesda, Maryland), and the densitometric intensity corresponding to each band was normalized against b-actin expression.
Immunofluorescence staining. Formaldehyde-fixed HK2 cells were incubated with a primary antibody against EPOR (1:100 dilution; Abcam), AA (Tian et al., 2008) (1:100 dilution), or LAMP1 (1:100 dilution; Abcam) at 4 C overnight and then incubated with a fluorescent secondary antibody (1:200 dilution at room temperature for 45 min; Abcam). The sections were counterstained with 4 0 ,6-diamidino-2-phenylindole (1:500 dilution; Sigma) to identify the cellular nuclei. The stained samples were observed under a confocal microscope (Leica Microsystems, Bannockburn, Illinois).
Synthetic EPOR peptides. Synthetic EPOR peptides were synthesized with a peptide synthesizer (Applied Biosystems 433A Peptide Synthesis System; Applied Biosystems, Foster City, California) and purified by reverse-phase HPLC with a C18 column (Agilent 1200 series; Agilent Technologies, Santa Clara, California). The synthetic EPOR peptides are the following: peptide 1, amino acids 1-20 (MDHLGASLWPQVGSLCLLLA); peptide 2, amino acids 66-85 (EAASAGVGPGNYSFSYQLED); and peptide 3, amino acids 39-58 (AALLAARGPEELLCFTERLE).
In situ hybridization with AA. The HK2 cell lysates were separated with a 10% native acrylamide gel and then transferred to a PVDF membrane (Millipore, Billerica, Massachusetts). The transfer membrane was incubated with AA in 2% blocking solution (TBST buffer with 2% BSA) for 4 h at room temperature. After washing with TBST buffer, the transfer membrane was stained with anti-AA antibody. In the competition test, the transfer membrane was incubated with 2% blocking solution containing synthetic EPOR peptides and AA for 4 h at room temperature. The concentrations of AA used in the test are described in the figure legends.
Molecular docking. Molecular docking was performed to investigate the interaction between AA and the EPOR using the SwissDock server and EADock program (Grosdidier et al., 2011) . The structure of the EPOR was adapted by computing the 3D structure reported previously (PDB: 1CN4) (Syed et al., 1998) . The binding modes were generated either through a local docking or in the vicinity of all of the target cavities. Their CHARMM energies were simultaneously estimated on a grid. The binding modes with the most favorable energies were evaluated with FACTS and clustered. The most favorable clusters were edited using the PyMOL software (Seeliger and de Groot, 2010) .
Spectrophotometric analysis. The synthetic EPOR peptides were dissolved in phosphate-buffered saline and incubated with AA at room temperature for 30 min in the dark. The experimental conditions and reagent concentrations employed for the spectrophotometric analysis are shown in the figure legends. The samples were analyzed in the wavelength range of 200-400 nm (SpectraMax M3, Molecular Devices, LLC, Sunnyvale, California).
Statistical analysis. All data were expressed as mean 6 SE. Oneway ANOVA with Bonferroni corrections was performed for analyzing the data of cell culture study. P values of <.05 were considered statistically significant.
RESULTS

Colocalization of AA and the EPOR in Zebrafish Embryos and HK2 Cells
To uncover the pathological roles of the EPOR in AA-induced anemia, we first stained AA-treated zebrafish embryos with specific antibodies against both AA and the EPOR. As a result, cells with green signals represented that AA were deposited inside, especially in the kidney region (Fig. 1A) . The EPOR-expressing cells were labeled in red signals (Fig. 1B) . Interestingly, green and red signal can be perfectly merged to obtain yellow signal (indicates by arrow), suggesting that AA and EPOR are colocalized in the kidney region of AA-treated zebrafish embryo (Fig. 1C) . Meanwhile, cultured human renal tubular HK2 cells that express the EPOR (Li et al., 2007) were used as an in vitro model for the cytotoxic study of AA. As shown in Figure 2A , no significant staining for AA was observed in HK2 cells that were not treated with AA (AA-; Fig. 2Aa-d ). After treatment with AA (5 and 10 mM), the AA-positive signals colocalized with the signals for the EPOR were presented major in the cytoplasm but few in the cell membrane (Figs. 2Bd and 2Cd) . Interestingly, the EPOR-positive signals were increased largely and detected in the cell membrane of HK2 cells after pretreated with EPO (Fig.  2Dc) . The immunofluorescent staining for AA and the EPOR in HK2 cells pretreated with EPO also showed the colocalization of the AA and EPOR signals ( Fig. 2D-d , -d 0 , yellow dots).
AA Impaired EPOR Signaling and Its Membrane Translocation
To further investigate the mutually effects of AA, EPO, and EPOR, we treated HK2 cell with different protocols, which comprised combinations of 3 doses (0, 1, and 20 mM) of AA and 2 doses of EPO (0 and 10 U). Following by immunofluorescent staining, the results showed that the EPOR is mostly located in the cytoplasm of starved HK2 cells (Figs. 3A, 3A 0 , 3A 00 , and 3a1).
EPO treatment can enhance the localization of the EPOR in the cell membrane of starved HK2 cells (Figs. 3B, 3B 0 , 3B 00 , 3b1, and 3b2). However, pretreatment with AA (1 and 20 mM) significantly lessened the membrane localization of the EPOR in starved HK2 cells treated with EPO (Figs. 3C, 3C 0 , 3C 00 , 3c1, 3D, 3D 0 , 3D 00 , and 3d1). The Western blotting results showed that EPO treatment significantly increased the phosphorylation of the EPOR, Akt, Erk1/2, and Jak in HK2 cells, particularly after treatment for 0.5 and 2 h (Fig. 4A) . Pre-treatment with AA significantly lessened the phosphorylation of the EPOR, Erk1/2, Jak, and Akt induced by EPO (Fig. 4B ). These observations suggest (1) that EPO treatment enhances EPOR cell membrane localization can be lessened by AA and (2) that AA treatment is able to downregulate EPO/EPOR signaling.
AA Enhanced the Lysosomal Degradation of the EPOR
Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms (Schneider-Poetsch et al., 2010) . In cultured HK2 cells pretreated with cycloheximide (10 mg/ml), AA treatment (0, 1, 10, and 100 mM) significantly decreased the amount of EPOR in a dosage-dependent manner (Fig. 5A ), suggesting that AA may enhance EPOR degradation. To confirm this hypothesis, an in vitro study with the lysosome inhibitor, bafilomycin A1 (Tapper and Sundler, 1995) was conducted. The Western blotting results revealed that bafilomycin A1 treatment can reverse the decrease in the effects of the EPOR induced by AA (Fig. 5B) . The immunofluorescent staining for EPOR and LAMP1 (a lysosome marker; Mane et al., 1989) showed that very few EPOR located in the lysosome without AA treatment (Figs. 5C-a-d significantly increase the lysosomal localization of the EPOR in starved HK2 cells (Figs. 5D and 5E ).
Direct Targeting of AA to the EPOR The above-described results suggested that AA may impair the cellular localization of the EPOR and increase its lysosomal degradation. It has been hypothesized that AA may bind to the EPOR. To test this hypothesis, molecular docking was performed. The docking results suggested that AA may interact with the N-terminal 45 amino acids of the EPOR through hydrophobic forces (Fig. 6A) . The spectrometric analysis using synthetic EPOR peptides and AA showed that the peptides spanning amino acids 1-85 can decrease the light absorption of AA at the spectrum of 250 and 320 nm. Among the synthetic EPOR peptides, synthetic peptide 3, which contained amino acids 39-58 of the EPOR, decreased the OD 250 and OD 320 values of AA most prominently (Fig. 6B) . The in situ hybridization with AA and separated HK2 cell lysates showed that AA may bind to a protein with a molecular weight similar to that of the EPOR. Negative staining was observed when the anti-AA antibody was replaced with nonspecific IgG (Fig. 6C) . We further performed a competition analysis with synthetic peptide 3, which significantly interacted with AA, as determined through light absorption analysis. The study results showed that synthetic peptide 3 can compete with the interaction between AA and a protein with a molecular weight similar to that of EPOR in a dosagedependent manner (Fig. 6D) . In summary, EPORs are transported to the cell membrane in the absence of AA. In AA-treated cells, AA can bind to the EPOR, and the EPOR-AA complex can then be transported to the lysosome for further degradation (Fig. 7) .
DISCUSSIONS
Severe anemia is a serious complication of AA nephropathy Reginster et al., 1997) . A previous study with a mouse model of AA nephropathy revealed that EPO supplementation significantly ameliorates acute tubular injury and interstitial inflammation by increasing the survival of tubular cells. However, the study results showed that EPO supplementation has minimal effects on AA-related anemia (Hamano et al., 2010) . It has been suggested that the diminished EPO production due to tubulointerstitial fibrosis caused by AA may not be the main cause of AA-related anemia. Our study results indicate that AA impairs EPOR signaling. By direct targeting, AA impairs the membrane localization of the EPOR upon EPO stimulation. In addition, the results also noted that AA accelerates the lysosomal degradation of the EPOR. The results of this study not only provide a novel insight for studying the pathological mechanisms of severe anemia complicated by AA nephropathy, but also explain why EPO supplementation fails to increase the hematocrit of the study mice with AA nephropathy. EPO production is from the liver and embryonic kidney in the fetus and completely switches to the kidney postnatally (Moritz et al., 1997; Wintour et al., 1996) . In adult animal, EPO is produced by kidney cells and transported to erythroid cells to promote blood cells maturation. The EPOR-expressing level in kidney cells (HK2, EPO-producing cells) is lower than that in erythroid cells (EPO-receiving cells). It could provide more information about the pathological mechanism of AA-induced anemia, if AA treatment impairs EPOR localization could be examined in the erythroid cells.
Our previous study using a zebrafish model of AA nephropathy showed that AA treatment impairs the blood circulation and induces cardiac malformation in the study zebrafish (Ding and Chen, 2012) . EPO and its receptor play an important physiological role in the cardiovascular system. EPO has been shown to increase NO production by increasing eNOS expression in endothelial cells both in vitro and in vivo (Banerjee et al., 2000; Beleslin-Cokic et al., 2004; d'Uscio et al., 2007; Kanagy et al., 2003) . The EPO system can facilitate cardiomyocyte survival after ischemia-reperfusion injury (Tada et al., 2006) . Defects in the EPO/EPOR system can result in pressure overload-induced cardiac dysfunction by accelerating left ventricular hypertrophy (Asaumi et al., 2007) . The animal model revealed that mice lacking the EPOR exhibit severe anemia and cardiac defect and die at the embryonic stage (Yu et al., 2001) . Defects in the EPO/EPOR system induced by AA, as was found in this study, may also be the possible cause of circulation failure and cardiac malformation in zebrafish intoxicated with AA.
In conclusion, we have demonstrated that AA may directly target the N-terminus of EPOR. The interaction between AA and the EPOR may result in defects in EPOR signaling by impairing the membrane localization and enhancing receptor degradation. The defects in the EPO/EPOR system induced by AA may account for the pathological mechanisms responsible for the severe anemia and other complications associated with AA intoxication. 
